Millennium Management
PTHS

Millennium Management’s Pelthos Therapeutics PTHS Stock Holding History

Millennium Management’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,057
Closed -$343K – 6494
2025
Q4 		$343K Buy
+11,057
New +$319K ﹤0.01% 5184
2025
Q3 		– Sell
-13,671
Closed -$172K – 6539
2025
Q2 		$172K Buy
+13,671
New +$165K ﹤0.01% 5411

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Millennium Management's PTHS Position: Q1 2026 in Review

Millennium Management sold out of Pelthos Therapeutics (PTHS) in Q1 2026, closing a stake of 11,057 shares — an estimated $343K sold.

Millennium Management first reported a position in PTHS in Q2 2025 and held it in 2 quarters. The position peaked at $343K in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Millennium Management reported no remaining Pelthos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 11,057 Pelthos Therapeutics shares in Q1 2026, an estimated $343K.
  • Millennium Management first reported a position in Pelthos Therapeutics in Q2 2025 and held it in 2 quarters.
  • Millennium Management's Pelthos Therapeutics position peaked at $343K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.